Shares of Glaukos (GKOS) plunged 13.2% in the pre-market trading session on Friday, February 21, 2025, as the medical technology firm reported a wider-than-expected net loss for the fourth quarter of 2024.
Glaukos posted a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss. While the company recorded revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors, leading to the significant stock decline.
Additionally, Glaukos forecasted full-year 2025 sales in the range of $475 million to $485 million, compared to the consensus estimate of $479.8 million. The company's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。